Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026

Stock Information for Biomea Fusion Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Biomea Fusion Inc.

Biomea Fusion to Participate at Upcoming Investor Conferences
Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones
Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference
Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025
Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Biomea Fusion to Participate at Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.